These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Nakase H; Chiba T Inflamm Bowel Dis; 2010 Apr; 16(4):550-1. PubMed ID: 19637380 [No Abstract] [Full Text] [Related]
54. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934 [TBL] [Abstract][Full Text] [Related]
55. Response to: infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. Tung J; Enders FT; Loftus EV J Crohns Colitis; 2014 Oct; 8(10):1327-8. PubMed ID: 24631323 [No Abstract] [Full Text] [Related]
56. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Tsai HH; Black C Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457 [TBL] [Abstract][Full Text] [Related]
57. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis. Hindson J Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497 [No Abstract] [Full Text] [Related]
58. THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era. Kotze PG; Damião AO; Moraes AC Arq Gastroenterol; 2016; 53(1):3-4. PubMed ID: 27276096 [No Abstract] [Full Text] [Related]
59. Development of antibodies against humanized antitumor necrosis factor and loss of efficacy in a black spider monkey with inflammatory bowel disease. Eekman DA; Hoyer MJ; van Vugt RM; Wolbink GJ; Mulder CJ; Dijkmans BA J Clin Rheumatol; 2009 Feb; 15(1):39. PubMed ID: 19125133 [No Abstract] [Full Text] [Related]